Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Comment on: “Diagnosis of Periprosthetic Joint Infection: The Role of Nuclear Medicine May Be Overestimated” by Claudio Diaz-Ledezma, Courtney Lamberton, Paul Lichtstein and Javad Parvizi
Published in: Journal of Arthroplasty
Access to document
10.1016/j.arth.2015.07.002
Andor W. J. M. Glaudemans, Paul C. Jutte, Nicola Petrosillo, Paola A. Erba, Elena Lazzeri, Alberto Signore
Imaging fungal infections in children
Published in: Clinical and Translational Imaging
Access to document
10.1007/s40336-015-0159-2
document
Fungal infections in children rarely occur, but continue to have a high morbidity and mortality despite the development of newer antifungal agents. It is essential for these infections to be diagnosed at the earliest possible stage so appropriate treatment can be initiated promptly. The addition of high-resolution computer tomography (HR CT) has helped in early diagnosis making; however, it lacks both sensitivity and specificity. Metabolic changes precede anatomical changes and hybrid imaging with positron emission tomography (PET) integrated with imaging modalities with high anatomical resolution such as CT...
Alfred O. Ankrah, Mike M Sathekge, Rudi A.J.O. Dierckx, Andor W.J.M. Glaudemans
Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.115.157974
Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 different PET tracers have been or are presently being tested. With a good rationale, after development of the tracer and proven feasibility, it is of interest to evaluate whether there is a potential meaningful role for the tracer in the clinical setting-such as in staging, in the (early) prediction of a treatment response, or in supporting drug choices. So far, only F-18-FDG PET has been incorporated into breast cancer guidelines. For proof...
Suzanne C van Es, Clasina M Venema, Andor W J M Glaudemans, Marjolijn N Lub-de Hooge, Sjoerd G Elias, Ronald Boellaard, Geke A.P. Hospers, Carolina P Schröder, Elisabeth G E de Vries
Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of alpha v beta 3 integrin expression
Published in: Journal of Nuclear Cardiology
Access to document
10.1007/s12350-014-0061-8
Background. Inflammation and angiogenesis play an important role in atherosclerotic plaque rupture. Therefore, molecular imaging of these processes could be used for determination of rupture-prone atherosclerotic plaques. alpha v beta 3 integrin is involved in the process of angiogenesis. Targeted imaging of alpha v beta 3 integrin has been shown to be possible in previous studies on tumor models, using radiolabeled arginine-glycine-aspartate (RGD). Our aim was to investigate feasibility of ex vivo detection of alpha v beta 3 integrin in carotid endarterectomy (CEA) specimens. Methods and Results. Nineteen...
Reza Golestani, Leila Mirfeizi, Clark J. Zeebregts, Johanna Westra, Hans J. de Haas, Andor W. J. M. Glaudemans, Michel Koole, Gert Luurtsema, Rene A. Tio, Rudi A. J. O. Dierckx, Hendrikus H. Boersma, Philip H. Elsinga, Riemer H. J. A. Slart
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment
Published in: Clinical Cancer Research
Access to document
10.1158/1078-0432.CCR-15-1272
PURPOSE: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers, making it a potential drug target. We performed an 89Zr-PET imaging study with MMOT0530A, a MSLN antibody, in conjunction with a phase I study with the antibody-drug conjugate DMOT4039A, containing MMOT0530A bound to MMAE. The aim was to study antibody tumor uptake, whole body distribution and relation between uptake, response to treatment and MSLN expression. EXPERIMENTAL DESIGN: Before DMOT4039A treatment, patients received 37 MBq 89Zr-MMOT0530A followed by PET/CT imaging 2, 4, and 7 days post injection (pi)....
Titia E Lamberts, Catharina W Menke-van der Houven van Oordt, Eva J Ter Weele, Frederike Bensch, Michiel M Smeenk, Johannes Voortman, Otto S Hoekstra, Simon P Williams, Bernard M Fine, Daniel Maslyar, Johan R. de Jong, Jourik A Gietema, Carolina P Schröder, Alfons H H Bongaerts, Marjolijn N Lub-de Hooge, Henk M W Verheul, Sandra Sanabria Bohorquez, Andor W J M Glaudemans, Elisabeth G de Vries